BBIO
BridgeBio Pharma, Inc.
Price Chart
Latest Quote
$67.39
+0.75 (+1.13%)
Current Price
| Previous Close | $66.64 |
| Open | $66.67 |
| Day High | $68.61 |
| Day Low | $66.30 |
| Volume | 1,575,341 |
Stock Information
| Shares Outstanding | 195.86M |
| Total Debt | $2.49B |
| Cash Equivalents | $940.19M |
| Revenue | $579.96M |
| Net Income | $-721.55M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $13.20B |
| EPS (TTM) | $-3.74 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $14.61B |
| Sales | $579.96M |
| Income | $-721.55M |
| Book/sh | $-11.64 |
| Cash/sh | $4.80 |
| Employees | 834 |
Financial Ratios
| Quick Ratio | 1.40 |
| Current Ratio | 1.52 |
Returns & Margins
| ROA | -27.98% |
| Gross Margin | 95.13% |
| Operating Margin | -54.47% |
| Profit Margin | -124.42% |
Ownership
| Insider Ownership | 3.90% |
| Institutional Ownership | 103.19% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 136.11 |
| P/S | 22.76 |
| P/B | -5.79 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $102.28 |
Technical Indicators
| SMA20 | $67.25 |
| SMA50 | $69.82 |
| SMA200 | $67.47 |
| RSI | 46.02 |
| ATR | 2.4361 |
| Shares Float | 152.80M |
| Short Float | 13.90% |
| Short Ratio | 9.02 |
| Volatility | 0.97 |
| Rel Volume | 0.58 |
Performance History
| Week | -0.02% |
| Month | +3.17% |
| Quarter | -3.89% |
| 6 Months | -9.56% |
| YTD | -13.86% |
| Year | +63.81% |
| 3 Years | +326.25% |
| 5 Years | +8.17% |
| 10 Years | +144.61% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-17 | $67.39 | 1,575,341 |
| 2026-06-16 | $66.64 | 2,738,200 |
| 2026-06-15 | $68.00 | 3,087,100 |
| 2026-06-12 | $66.80 | 1,545,500 |
| 2026-06-11 | $67.55 | 2,535,100 |
| 2026-06-10 | $67.40 | 2,128,400 |
| 2026-06-09 | $67.68 | 1,837,000 |
| 2026-06-08 | $67.37 | 1,751,900 |
| 2026-06-05 | $67.61 | 2,590,000 |
| 2026-06-04 | $67.33 | 1,968,900 |
| 2026-06-03 | $65.48 | 2,741,400 |
| 2026-06-02 | $63.88 | 4,697,300 |
| 2026-06-01 | $65.36 | 8,117,300 |
| 2026-05-29 | $66.26 | 3,052,300 |
| 2026-05-28 | $68.45 | 2,180,600 |
| 2026-05-27 | $66.44 | 3,022,900 |
| 2026-05-26 | $67.73 | 2,422,700 |
| 2026-05-22 | $69.12 | 1,826,400 |
| 2026-05-21 | $70.28 | 2,297,100 |
| 2026-05-20 | $68.22 | 2,608,600 |
| 2026-05-19 | $66.00 | 2,420,100 |
| 2026-05-18 | $65.32 | 3,415,400 |
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease. In addition, the company engages in developing products for mendelian, oncology, and gene therapy diseases. It has license and collaboration agreements with the Bayer Consumer Care AG, Alexion Pharma International Operations Limited Company, Leland Stanford Junior University, and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
đ° Latest News
Here Are Wednesdayâs Top Wall Street Analyst Research Calls: Boyd Gaming, Chipotle Mexican Grill, Conagra, Dollar General, MGM Resorts International, Omnicom Group, Yum! Brands, and More
24/7 Wall St. âĸ 2026-06-03T17:08:00Z
Yum! Brands upgraded, Chipotle downgraded: Wall Street's top analyst calls
The Fly âĸ 2026-06-03T13:55:44Z
Does FDA Priority Review for First LGMD Therapy Change The Bull Case For BridgeBio Pharma (BBIO)?
Simply Wall St. âĸ 2026-06-01T03:07:18Z
Allogene CEO to step down; Agios drug fails key test
BioPharma Dive âĸ 2026-05-29T10:17:00Z
Intel downgraded, Marvell upgraded: Wall Street's top analyst calls
The Fly âĸ 2026-05-26T13:34:48Z
Citi Initiates BridgeBio at Neutral: Why the Cardiomyopathy Story Isnât a Slam Dunk
24/7 Wall St. âĸ 2026-05-19T16:15:16Z
StubHub, Jazz Pharmaceuticals upgraded: Wall Street's top analyst calls
The Fly âĸ 2026-05-19T13:34:39Z
How Encaleretâs NDA and New Acoramidis Milestones Could Reframe BridgeBio Pharma (BBIO) Investorsâ Outlook
Simply Wall St. âĸ 2026-05-15T05:13:18Z
Evercore ISI Retains an âOutperform Ratingâ on BridgeBio Pharma, Inc. (BBIO)
Insider Monkey âĸ 2026-05-13T17:53:16Z
BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches
MarketBeat âĸ 2026-05-13T05:04:31Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $20,962,000 | $3,878,000 | $2,446,000 | $3,434,000 |
| Cost Of Revenue | $20,962,000 | $3,878,000 | $2,446,000 | $3,434,000 |
| Total Revenue | $502,076,000 | $221,902,000 | $9,303,000 | $77,648,000 |
| Operating Revenue | $502,076,000 | $221,902,000 | $9,303,000 | $77,648,000 |
| Expenses | ||||
| Interest Expense | $178,241,000 | $99,290,000 | $81,289,000 | $80,438,000 |
| Total Expenses | $1,004,140,000 | $799,270,000 | $608,747,000 | $546,085,000 |
| Other Income Expense | $-72,052,000 | $117,215,000 | $9,444,000 | $56,681,000 |
| Other Non Operating Income Expenses | $43,058,000 | $12,272,000 | $17,370,000 | $108,668,000 |
| Net Non Operating Interest Income Expense | $-158,387,000 | $-82,041,000 | $-63,251,000 | $-72,896,000 |
| Interest Expense Non Operating | $178,241,000 | $99,290,000 | $81,289,000 | $80,438,000 |
| Operating Expense | $983,178,000 | $795,392,000 | $606,301,000 | $542,651,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-724,931,000 | $-535,762,000 | $-643,202,000 | $-481,183,000 |
| Net Interest Income | $-158,387,000 | $-82,041,000 | $-63,251,000 | $-72,896,000 |
| Interest Income | $19,854,000 | $17,249,000 | $18,038,000 | $7,542,000 |
| Normalized Income | $-691,354,420 | $-643,301,540 | $-635,276,000 | $-429,196,000 |
| Net Income From Continuing And Discontinued Operation | $-724,931,000 | $-535,762,000 | $-643,202,000 | $-481,183,000 |
| Total Operating Income As Reported | $-523,411,000 | $-592,973,000 | $-607,370,000 | $-512,202,000 |
| Net Income Common Stockholders | $-724,931,000 | $-535,762,000 | $-643,202,000 | $-481,183,000 |
| Net Income | $-724,931,000 | $-535,762,000 | $-643,202,000 | $-481,183,000 |
| Net Income Including Noncontrolling Interests | $-732,938,000 | $-543,347,000 | $-653,251,000 | $-484,652,000 |
| Net Income Continuous Operations | $-732,938,000 | $-543,347,000 | $-653,251,000 | $-484,652,000 |
| Pretax Income | $-732,503,000 | $-542,194,000 | $-653,251,000 | $-484,652,000 |
| Special Income Charges | $-42,502,000 | $136,126,000 | $-7,926,000 | $-43,765,000 |
| Earnings From Equity Interest | $-72,608,000 | $-31,183,000 | $0 | $0 |
| Interest Income Non Operating | $19,854,000 | $17,249,000 | $18,038,000 | $7,542,000 |
| Operating Income | $-502,064,000 | $-577,368,000 | $-599,444,000 | $-468,437,000 |
| Gross Profit | $481,114,000 | $218,024,000 | $6,857,000 | $74,214,000 |
| Per Share | ||||
| Diluted EPS | $-3.78 | $-2.88 | $-3.95 | $-3.26 |
| Basic EPS | $-3.78 | $-2.88 | $-3.95 | $-3.26 |
| Other | ||||
| Tax Effect Of Unusual Items | $-8,925,420 | $28,586,460 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-506,326,000 | $-572,955,000 | $-557,542,000 | $-345,456,000 |
| Total Unusual Items | $-42,502,000 | $136,126,000 | $-7,926,000 | $-51,987,000 |
| Total Unusual Items Excluding Goodwill | $-42,502,000 | $136,126,000 | $-7,926,000 | $-51,987,000 |
| Reconciled Depreciation | $5,434,000 | $6,075,000 | $6,494,000 | $6,771,000 |
| EBITDA (Bullshit earnings) | $-548,828,000 | $-436,829,000 | $-565,468,000 | $-397,443,000 |
| EBIT | $-554,262,000 | $-442,904,000 | $-571,962,000 | $-404,214,000 |
| Diluted Average Shares | $191,527,482 | $186,075,873 | $162,791,511 | $147,473,076 |
| Basic Average Shares | $191,527,482 | $186,075,873 | $162,791,511 | $147,473,076 |
| Diluted NI Availto Com Stockholders | $-724,931,000 | $-535,762,000 | $-643,202,000 | $-481,183,000 |
| Minority Interests | $8,007,000 | $7,585,000 | $10,049,000 | $3,469,000 |
| Tax Provision | $435,000 | $1,153,000 | $0 | $0 |
| Gain On Sale Of Business | $0 | $178,321,000 | $0 | $0 |
| Other Special Charges | $21,155,000 | $26,590,000 | - | - |
| Impairment Of Capital Assets | $0 | $271,000 | $0 | $12,720,000 |
| Restructuring And Mergern Acquisition | $21,347,000 | $15,334,000 | $7,926,000 | $31,045,000 |
| Research And Development | $451,953,000 | $506,461,000 | $455,711,000 | $399,462,000 |
| Selling General And Administration | $531,225,000 | $288,931,000 | $150,590,000 | $143,189,000 |
| Gain On Sale Of Security | - | $8,136,000 | $18,300,000 | $-8,222,000 |
| Write Off | - | - | $7,211,000 | $20,739,000 |
| Gain On Sale Of Ppe | - | - | - | $-6,300,000 |
Fetched: 2026-06-16
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-2,114,687,000 | $-1,491,830,000 | $-1,380,576,000 | $-1,283,329,000 |
| Total Assets | $936,025,000 | $919,338,000 | $546,380,000 | $623,036,000 |
| Total Non Current Assets | $138,276,000 | $198,646,000 | $68,787,000 | $74,183,000 |
| Other Non Current Assets | $16,712,000 | $18,195,000 | $22,625,000 | $20,224,000 |
| Goodwill And Other Intangible Assets | $28,077,000 | $23,926,000 | $26,319,000 | $28,712,000 |
| Current Assets | $797,749,000 | $720,692,000 | $477,593,000 | $548,853,000 |
| Other Current Assets | $44,070,000 | $34,869,000 | $24,305,000 | $21,922,000 |
| Inventory | $26,753,000 | $0 | - | - |
| Receivables | $139,444,000 | $4,722,000 | $1,751,000 | $17,079,000 |
| Accounts Receivable | $139,444,000 | $4,722,000 | $1,751,000 | - |
| Cash Cash Equivalents And Short Term Investments | $587,482,000 | $681,101,000 | $434,884,000 | $471,922,000 |
| Cash And Cash Equivalents | $570,119,000 | $681,101,000 | $375,935,000 | $376,689,000 |
| Restricted Cash | - | $126,000 | $16,653,000 | $37,930,000 |
| Other Receivables | - | - | $1,751,000 | $17,079,000 |
| Other Intangible Assets | - | - | - | $28,712,000 |
| Prepaid Assets | - | - | - | $21,922,000 |
| Debt | ||||
| Net Debt | $1,282,351,000 | $1,040,281,000 | $1,350,794,000 | $1,330,926,000 |
| Total Debt | $1,862,473,000 | $1,730,584,000 | $1,739,838,000 | $1,723,564,000 |
| Long Term Debt And Capital Lease Obligation | $1,856,281,000 | $1,726,078,000 | $1,735,710,000 | $1,719,889,000 |
| Long Term Debt | $1,852,470,000 | $1,721,382,000 | $1,726,729,000 | $1,707,615,000 |
| Current Debt And Capital Lease Obligation | $6,192,000 | $4,506,000 | $4,128,000 | $3,675,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $3,012,606,000 | $2,376,950,000 | $1,888,915,000 | $1,867,960,000 |
| Total Non Current Liabilities Net Minority Interest | $2,724,635,000 | $2,222,550,000 | $1,745,071,000 | $1,746,532,000 |
| Other Non Current Liabilities | $244,000 | $286,000 | $5,634,000 | $26,643,000 |
| Non Current Deferred Liabilities | $868,110,000 | $496,186,000 | $3,727,000 | - |
| Current Liabilities | $287,971,000 | $154,400,000 | $143,844,000 | $121,428,000 |
| Current Deferred Liabilities | $18,411,000 | $14,748,000 | $6,096,000 | $8,156,000 |
| Payables And Accrued Expenses | $186,665,000 | $76,817,000 | $76,250,000 | $78,341,000 |
| Interest Payable | $14,411,000 | $11,056,000 | $17,761,000 | $17,500,000 |
| Payables | $36,228,000 | $9,618,000 | $10,655,000 | $11,558,000 |
| Accounts Payable | $36,228,000 | $9,618,000 | $10,655,000 | $11,558,000 |
| Equity | ||||
| Common Stock Equity | $-2,086,610,000 | $-1,467,904,000 | $-1,354,257,000 | $-1,254,617,000 |
| Total Equity Gross Minority Interest | $-2,076,581,000 | $-1,457,612,000 | $-1,342,535,000 | $-1,244,924,000 |
| Stockholders Equity | $-2,086,610,000 | $-1,467,904,000 | $-1,354,257,000 | $-1,254,617,000 |
| Gains Losses Not Affecting Retained Earnings | $12,000 | $8,000 | $31,000 | $-328,000 |
| Other Equity Adjustments | $12,000 | $8,000 | $31,000 | $-328,000 |
| Retained Earnings | $-3,821,194,000 | $-3,096,263,000 | $-2,560,501,000 | $-1,918,149,000 |
| Long Term Equity Investment | $79,972,000 | $143,747,000 | $0 | - |
| Other | ||||
| Treasury Shares Number | $7,597,172 | $6,191,761 | $6,191,761 | $6,191,761 |
| Ordinary Shares Number | $194,771,957 | $190,044,473 | $175,082,951 | $150,625,572 |
| Share Issued | $202,369,129 | $196,236,234 | $181,274,712 | $156,817,333 |
| Tangible Book Value | $-2,114,687,000 | $-1,491,830,000 | $-1,380,576,000 | $-1,283,329,000 |
| Invested Capital | $-234,140,000 | $253,478,000 | $372,472,000 | $452,998,000 |
| Working Capital | $509,778,000 | $566,292,000 | $333,749,000 | $427,425,000 |
| Capital Lease Obligations | $10,003,000 | $9,202,000 | $13,109,000 | $15,949,000 |
| Total Capitalization | $-234,140,000 | $253,478,000 | $372,472,000 | $452,998,000 |
| Minority Interest | $10,029,000 | $10,292,000 | $11,722,000 | $9,693,000 |
| Treasury Stock | $323,276,000 | $275,000,000 | $275,000,000 | $275,000,000 |
| Additional Paid In Capital | $2,057,646,000 | $1,903,155,000 | $1,481,032,000 | $938,703,000 |
| Capital Stock | $202,000 | $196,000 | $181,000 | $157,000 |
| Common Stock | $202,000 | $196,000 | $181,000 | $157,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $13,080,000 | $17,095,000 | $3,727,000 | - |
| Long Term Capital Lease Obligation | $3,811,000 | $4,696,000 | $8,981,000 | $12,274,000 |
| Current Deferred Revenue | $7,190,000 | $14,604,000 | $6,096,000 | $8,156,000 |
| Current Capital Lease Obligation | $6,192,000 | $4,506,000 | $4,128,000 | $3,675,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $76,703,000 | $58,329,000 | $57,370,000 | $31,256,000 |
| Current Accrued Expenses | $150,437,000 | $67,199,000 | $65,595,000 | $66,783,000 |
| Investments And Advances | $79,972,000 | $143,747,000 | $0 | - |
| Net PPE | $13,515,000 | $12,778,000 | $19,843,000 | $25,247,000 |
| Gross PPE | $13,515,000 | $12,778,000 | $19,843,000 | $25,247,000 |
| Other Properties | $13,515,000 | $12,778,000 | $19,843,000 | $25,247,000 |
| Other Short Term Investments | $17,363,000 | $0 | $58,949,000 | $95,233,000 |
Fetched: 2026-06-16
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-455,502,000 | $-529,634,000 | $-529,026,000 | $-425,815,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-445,910,000 | $-520,726,000 | $-527,720,000 | $-419,494,000 |
| Cash Flow From Continuing Operating Activities | $-445,910,000 | $-520,726,000 | $-527,720,000 | $-419,494,000 |
| Operating Gains Losses | $84,930,000 | $-128,684,000 | $-17,073,000 | $14,483,000 |
| Investing Activities | ||||
| Capital Expenditure | $-9,592,000 | $-8,908,000 | $-1,306,000 | $-6,321,000 |
| Investing Cash Flow | $-24,487,000 | $60,781,000 | $54,033,000 | $453,147,000 |
| Cash Flow From Continuing Investing Activities | $-24,487,000 | $60,781,000 | $54,033,000 | $453,147,000 |
| Net Other Investing Changes | - | - | $-503,000 | $120,000,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-62,502,000 | $-7,526,000 | $-6,880,000 | $-1,561,000 |
| Issuance Of Capital Stock | $0 | $314,741,000 | $449,810,000 | $4,852,000 |
| Financing Cash Flow | $359,293,000 | $748,457,000 | $451,535,000 | $-13,134,000 |
| Cash Flow From Continuing Financing Activities | $359,293,000 | $748,457,000 | $451,535,000 | $-13,134,000 |
| Net Other Financing Charges | $271,646,000 | $456,501,000 | $-801,000 | $837,000 |
| Net Common Stock Issuance | $-62,502,000 | $307,215,000 | $442,930,000 | $3,291,000 |
| Common Stock Issuance | $0 | $314,741,000 | $449,810,000 | $4,852,000 |
| Dividends Received Cfi | $2,302,000 | $25,682,000 | $0 | $0 |
| Other | ||||
| Repayment Of Debt | $-459,000,000 | $-473,417,000 | $0 | $-20,486,000 |
| Issuance Of Debt | $575,000,000 | $450,000,000 | $0 | $0 |
| Interest Paid Supplemental Data | $43,760,000 | $91,342,000 | $61,108,000 | $54,443,000 |
| Income Tax Paid Supplemental Data | $1,198,000 | - | - | - |
| End Cash Position | $572,140,000 | $683,244,000 | $394,732,000 | $416,884,000 |
| Beginning Cash Position | $683,244,000 | $394,732,000 | $416,884,000 | $396,365,000 |
| Changes In Cash | $-111,104,000 | $288,512,000 | $-22,152,000 | $20,519,000 |
| Proceeds From Stock Option Exercised | $34,149,000 | $8,158,000 | $9,406,000 | $3,224,000 |
| Common Stock Payments | $-62,502,000 | $-7,526,000 | $-6,880,000 | $-1,561,000 |
| Net Issuance Payments Of Debt | $116,000,000 | $-23,417,000 | $0 | $-20,486,000 |
| Net Long Term Debt Issuance | $116,000,000 | $-23,417,000 | $0 | $-20,486,000 |
| Long Term Debt Payments | $-459,000,000 | $-473,417,000 | $0 | $-20,486,000 |
| Long Term Debt Issuance | $575,000,000 | $450,000,000 | $0 | $0 |
| Net Investment Purchase And Sale | $-17,197,000 | $44,147,000 | $55,842,000 | $339,468,000 |
| Sale Of Investment | $11,000,000 | $158,229,000 | $193,106,000 | $532,523,000 |
| Purchase Of Investment | $-28,197,000 | $-114,082,000 | $-137,264,000 | $-193,055,000 |
| Net Business Purchase And Sale | $0 | $-140,000 | $-503,000 | $0 |
| Purchase Of Business | $0 | $-140,000 | $-503,000 | $0 |
| Net Intangibles Purchase And Sale | $-8,495,000 | $-7,975,000 | $0 | $-1,500,000 |
| Purchase Of Intangibles | $-8,495,000 | $-7,975,000 | $0 | $-1,500,000 |
| Net PPE Purchase And Sale | $-1,097,000 | $-933,000 | $-1,306,000 | $-4,821,000 |
| Purchase Of PPE | $-1,097,000 | $-933,000 | $-1,306,000 | $-4,821,000 |
| Change In Working Capital | $-51,064,000 | $32,042,000 | $5,057,000 | $28,079,000 |
| Change In Other Working Capital | $66,382,000 | $26,064,000 | $-1,921,000 | $15,262,000 |
| Change In Other Current Liabilities | $-6,547,000 | $-5,902,000 | $-4,829,000 | $-6,245,000 |
| Change In Other Current Assets | $1,113,000 | $1,542,000 | $-1,546,000 | $10,971,000 |
| Change In Payables And Accrued Expense | $56,794,000 | $27,227,000 | $727,000 | $-14,749,000 |
| Change In Accrued Expense | $30,185,000 | $25,715,000 | $-2,053,000 | $-14,400,000 |
| Change In Payable | $26,609,000 | $1,512,000 | $2,780,000 | $-349,000 |
| Change In Account Payable | $26,609,000 | $1,512,000 | $2,780,000 | $-349,000 |
| Change In Prepaid Assets | $-8,777,000 | $-13,918,000 | $-2,702,000 | $7,671,000 |
| Change In Inventory | $-25,307,000 | $0 | $0 | - |
| Change In Receivables | $-134,722,000 | $-2,971,000 | $15,328,000 | $15,169,000 |
| Changes In Account Receivables | $-134,722,000 | $-2,971,000 | $15,328,000 | $15,169,000 |
| Other Non Cash Items | $136,007,000 | $19,873,000 | $23,146,000 | $-88,454,000 |
| Stock Based Compensation | $133,024,000 | $95,800,000 | $108,710,000 | $91,559,000 |
| Unrealized Gain Loss On Investment Securities | $-21,303,000 | $-2,485,000 | $-803,000 | - |
| Depreciation Amortization Depletion | $5,434,000 | $6,075,000 | $6,494,000 | $6,771,000 |
| Depreciation And Amortization | $5,434,000 | $6,075,000 | $6,494,000 | $6,771,000 |
| Earnings Losses From Equity Investments | $72,608,000 | $31,183,000 | $0 | $0 |
| Gain Loss On Investment Securities | $-8,833,000 | $-8,136,000 | $-18,314,000 | $8,222,000 |
| Gain Loss On Sale Of Business | $0 | $-178,321,000 | $1,241,000 | $0 |
| Net Income From Continuing Operations | $-732,938,000 | $-543,347,000 | $-653,251,000 | $-484,652,000 |
| Asset Impairment Charge | - | $271,000 | $0 | $12,720,000 |
Fetched: 2026-06-16